logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11078198 B1

PDFFull Text
Date of Patent:
Aug. 03, 2021

Filed:

Oct. 31, 2018

Spirocyclic compounds as farnesoid x receptor modulators

Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Joseph E. Carpenter, Plainsboro, NJ (US);

Yanting Huang, Pennington, NJ (US);

Ying Wang, New Hope, PA (US);

Gang Wu, Princeton, NJ (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:

Gary Greenblatt

Primary Examiner:

Amanda L Aguirre

Int. Cl.
CPC ...
C07D 261/08 (2006.01); C07D 263/32 (2006.01); C07D 401/14 (2006.01); C07D 413/08 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/10 (2006.01); C07D 491/107 (2006.01); C07D 491/113 (2006.01); C07D 491/20 (2006.01); C07D 513/04 (2006.01); A61K 31/42 (2006.01); A61K 31/428 (2006.01); A61K 31/429 (2006.01); C07H 15/26 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 31/42 (2013.01); A61K 31/428 (2013.01); A61K 31/429 (2013.01); C07D 261/08 (2013.01); C07D 263/32 (2013.01); C07D 401/14 (2013.01); C07D 413/08 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C07D 491/107 (2013.01); C07D 491/113 (2013.01); C07D 491/20 (2013.01); C07D 513/04 (2013.01); C07H 15/26 (2013.01);
Abstract

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Find Patent Forward Citations

Loading…